MeSH term
Frequency | Condition_Probility | Acute Disease | 4 | 0.0 |
Adult | 424 | 0.0 |
Bone Marrow Transplantation/*statistics & numerical data | 2 | 2.0 |
Comparative Study | 186 | 0.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 2 | 2.0 |
Fetal Blood/transplantation | 2 | 2.0 |
Humans | 1193 | 0.0 |
Leukemia/*therapy | 2 | 1.0 |
Patient Selection | 2 | 1.0 |
Aged | 389 | 1.0 |
Risk | 4 | 0.0 |
Time Factors | 35 | 0.0 |
Drug Interactions | 3 | 0.0 |
Drug Therapy, Combination | 3 | 0.0 |
Animals | 181 | 0.0 |
DNA Damage | 18 | 2.0 |
DNA Repair | 16 | 2.0 |
Drug Resistance, Neoplasm | 3 | 0.0 |
Gene Expression | 27 | 0.0 |
Amino Acid Substitution | 4 | 0.0 |
Base Pairing | 2 | 3.0 |
Mice | 63 | 0.0 |
Protein Structure, Tertiary | 8 | 0.0 |
Research Support, Non-U.S. Gov't | 508 | 0.0 |
Antineoplastic Agents/pharmacology | 4 | 0.0 |
Apoptosis/drug effects | 10 | 1.0 |
Cell Cycle/drug effects | 10 | 1.0 |
Cell Division/*drug effects | 2 | 0.0 |
Cyclooxygenase Inhibitors/*pharmacology | 4 | 11.0 |
Dinoprostone/biosynthesis | 2 | 3.0 |
Nitrobenzenes/*pharmacology | 2 | 25.0 |
Proliferating Cell Nuclear Antigen/analysis | 158 | 63.0 |
RNA, Messenger/analysis | 11 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 19 | 0.0 |
S Phase/drug effects | 2 | 3.0 |
Sulfonamides/*pharmacology | 3 | 6.0 |
Tumor Cells, Cultured | 74 | 0.0 |
Actins/analysis | 6 | 3.0 |
Bone Marrow/pathology | 3 | 0.0 |
Endothelial Growth Factors/analysis | 5 | 6.0 |
Female | 584 | 0.0 |
Immunohistochemistry | 455 | 3.0 |
Lymphoid Tissue/*pathology | 2 | 14.0 |
Lymphokines/analysis | 5 | 5.0 |
Mouth Mucosa/pathology | 2 | 8.0 |
Mouth Neoplasms/*pathology | 3 | 13.0 |
Muscle, Smooth/pathology | 2 | 9.0 |
Neoplasm Invasiveness | 54 | 4.0 |
Neoplasm Proteins/analysis | 28 | 8.0 |
Protein Isoforms/analysis | 2 | 4.0 |
Vascular Endothelial Growth Factor A | 12 | 0.0 |
Vascular Endothelial Growth Factors | 12 | 0.0 |
von Willebrand Factor/analysis | 5 | 1.0 |
Cell Division/drug effects | 32 | 0.0 |
Isoenzymes/*antagonists & inhibitors | 2 | 6.0 |
Male | 489 | 0.0 |
Middle Aged | 483 | 0.0 |
Proliferating Cell Nuclear Antigen/metabolism | 77 | 38.0 |
Prostaglandin-Endoperoxide Synthase | 2 | 6.0 |
DNA Methylation | 2 | 0.0 |
DNA, Neoplasm/metabolism | 3 | 2.0 |
Gene Deletion | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 12 | 0.0 |
*Genes, Tumor Suppressor | 3 | 0.0 |
Promoter Regions (Genetics) | 7 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 177 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
*Tumor Suppressor Proteins | 7 | 0.0 |
CDC2 Protein Kinase/*metabolism | 2 | 1.0 |
*CDC2-CDC28 Kinases | 26 | 3.0 |
Cyclin-Dependent Kinases/*metabolism | 8 | 3.0 |
Electrophoresis, Polyacrylamide Gel | 14 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Hela Cells | 33 | 0.0 |
Immunoblotting | 14 | 0.0 |
Liver/enzymology | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 6 | 0.0 |
Adenocarcinoma/*metabolism/pathology | 4 | 3.0 |
Endometrial Neoplasms/*metabolism/pathology | 2 | 6.0 |
Proliferating Cell Nuclear Antigen/*biosynthesis | 52 | 94.0 |
Protein p53/*biosynthesis | 25 | 20.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 8 | 7.0 |
Aged, 80 and over | 176 | 1.0 |
Antibodies, Monoclonal | 53 | 2.0 |
Breast Neoplasms/*pathology | 3 | 1.0 |
Carcinoma, Ductal, Breast/pathology | 3 | 25.0 |
Carcinoma, Lobular/pathology | 2 | 40.0 |
Proliferating Cell Nuclear Antigen/*metabolism | 157 | 87.0 |
Receptor, erbB-2/*metabolism | 5 | 3.0 |
Receptors, Estrogen/*analysis | 3 | 1.0 |
Receptors, Progesterone/*analysis | 4 | 1.0 |
Binding Sites | 27 | 0.0 |
Cloning, Molecular | 13 | 0.0 |
DNA/metabolism | 14 | 0.0 |
Escherichia coli | 5 | 1.0 |
Protein Binding | 31 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 6 | 0.0 |
Biopsy | 32 | 1.0 |
Cell Differentiation | 19 | 0.0 |
Cell Division | 206 | 4.0 |
Epithelial Cells/pathology | 4 | 5.0 |
Phenotype | 9 | 0.0 |
Vimentin/biosynthesis | 2 | 14.0 |
English Abstract | 161 | 1.0 |
Gene Expression Regulation, Neoplastic | 36 | 1.0 |
Ki-67 Antigen/*biosynthesis | 4 | 15.0 |
Kidney Neoplasms/*metabolism/*pathology | 2 | 33.0 |
Prognosis | 252 | 4.0 |
*Oligonucleotide Array Sequence Analysis | 3 | 1.0 |
Proliferating Cell Nuclear Antigen/genetics | 18 | 62.0 |
Tumor Markers, Biological | 20 | 4.0 |
Amino Acid Motifs | 6 | 0.0 |
Amino Acid Sequence | 56 | 0.0 |
Cell Line | 57 | 0.0 |
Molecular Sequence Data | 75 | 0.0 |
Precipitin Tests | 9 | 0.0 |
Proliferating Cell Nuclear Antigen/chemistry/*metabolism | 4 | 80.0 |
Structure-Activity Relationship | 11 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Cluster Analysis | 2 | 1.0 |
*Gene Expression Profiling | 5 | 1.0 |
Immunoenzyme Techniques | 96 | 2.0 |
Lung Neoplasms/*genetics/metabolism/pathology | 2 | 9.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Survival Rate | 73 | 3.0 |
Cell Separation | 2 | 0.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Flow Cytometry | 60 | 0.0 |
In Vitro | 17 | 0.0 |
Base Sequence | 47 | 0.0 |
DNA Helicases/metabolism | 3 | 10.0 |
*DNA Replication | 30 | 12.0 |
DNA, Viral/*biosynthesis | 2 | 10.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
Models, Molecular | 7 | 0.0 |
Proliferating Cell Nuclear Antigen/genetics/metabolism | 4 | 50.0 |
Transcription Factors/metabolism | 7 | 0.0 |
DNA Primers | 18 | 0.0 |
DNA-Binding Proteins/chemistry/*metabolism | 2 | 1.0 |
Blotting, Western | 26 | 0.0 |
Neoplasm Proteins/*metabolism | 10 | 1.0 |
Proportional Hazards Models | 18 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 10 | 2.0 |
Survival Analysis | 66 | 2.0 |
Tumor Markers, Biological/*metabolism | 27 | 6.0 |
Microfilament Proteins/metabolism | 3 | 3.0 |
Tissue Distribution | 4 | 0.0 |
Transfection | 27 | 0.0 |
Carcinoma, Squamous Cell/*metabolism/mortality/pathology | 2 | 28.0 |
Cell Division/physiology | 43 | 5.0 |
Cyclin A/*biosynthesis | 2 | 22.0 |
Cyclin-Dependent Kinases/biosynthesis | 5 | 16.0 |
Laryngeal Neoplasms/*metabolism/mortality/pathology | 2 | 40.0 |
Multivariate Analysis | 37 | 2.0 |
Neoplasm Staging | 93 | 4.0 |
Protein-Serine-Threonine Kinases/biosynthesis | 4 | 13.0 |
Retrospective Studies | 86 | 2.0 |
Disease Progression | 25 | 0.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Acetylation | 3 | 0.0 |
Apoptosis/physiology | 5 | 1.0 |
Down-Regulation | 8 | 0.0 |
*Saccharomyces cerevisiae Proteins | 29 | 2.0 |
Blotting, Northern | 7 | 0.0 |
Cells, Cultured | 42 | 0.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Glutathione Transferase/genetics | 3 | 1.0 |
*Neoplasm Proteins | 2 | 0.0 |
Rats | 46 | 0.0 |
Rats, Sprague-Dawley | 12 | 0.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
Antigens, Neoplasm/analysis | 24 | 7.0 |
Carcinoembryonic Antigen/analysis | 6 | 5.0 |
Liver Cirrhosis/metabolism/pathology | 4 | 44.0 |
Liver Neoplasms/metabolism/pathology | 2 | 12.0 |
Microscopy, Electron | 11 | 0.0 |
Tumor Markers, Biological/*analysis | 76 | 7.0 |
Annexin A5/metabolism | 3 | 3.0 |
Antigens, CD34/analysis | 7 | 1.0 |
Biological Markers/analysis | 22 | 2.0 |
Case-Control Studies | 16 | 0.0 |
Caspases/metabolism | 3 | 0.0 |
Chronic Disease | 10 | 0.0 |
Prospective Studies | 13 | 0.0 |
Cattle | 14 | 0.0 |
DNA Polymerase III/*metabolism | 8 | 66.0 |
DNA Replication | 21 | 5.0 |
Kinetics | 25 | 0.0 |
Peptide Fragments | 2 | 2.0 |
Protein Subunits | 3 | 0.0 |
Recombinant Proteins/metabolism | 14 | 0.0 |
Sequence Alignment | 6 | 0.0 |
Sequence Homology, Amino Acid | 13 | 0.0 |
Spodoptera | 5 | 1.0 |
Thymus Gland/enzymology | 4 | 36.0 |
Cell Aging/*physiology | 2 | 3.0 |
Cyclins/*physiology | 2 | 3.0 |
Protein p16/physiology | 2 | 20.0 |
Analysis of Variance | 19 | 0.0 |
Ki-67 Antigen/analysis | 31 | 11.0 |
Nuclear Proteins/analysis | 44 | 26.0 |
Adolescent | 103 | 0.0 |
Antigens, Nuclear | 17 | 11.0 |
*Apoptosis | 27 | 1.0 |
Child | 58 | 0.0 |
Child, Preschool | 31 | 0.0 |
Infant | 21 | 0.0 |
Ki-67 Antigen | 60 | 28.0 |
Predictive Value of Tests | 38 | 1.0 |
Protein p53/analysis | 33 | 11.0 |
Proto-Oncogene Proteins/analysis | 8 | 4.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 16 | 8.0 |
Biological Markers | 27 | 1.0 |
Cell Nucleus/metabolism | 10 | 0.0 |
Adenocarcinoma/*pathology | 2 | 2.0 |
Cell Cycle/*drug effects | 2 | 1.0 |
Cyclin A/metabolism | 3 | 3.0 |
Cyclin B/metabolism | 4 | 4.0 |
Cyclin D1/metabolism | 5 | 3.0 |
Cyclins/metabolism | 11 | 2.0 |
Protein p16/metabolism | 2 | 3.0 |
Stomach Neoplasms/*pathology | 2 | 4.0 |
*DNA Repair | 29 | 4.0 |
Fibroblasts/metabolism/radiation effects | 2 | 10.0 |
Models, Biological | 7 | 0.0 |
Ultraviolet Rays | 16 | 2.0 |
*Adenosinetriphosphatase | 2 | 2.0 |
*Base Pair Mismatch | 2 | 2.0 |
*DNA-Binding Proteins | 12 | 0.0 |
Escherichia coli/genetics | 3 | 0.0 |
Saccharomyces cerevisiae/genetics | 3 | 0.0 |
Schizosaccharomyces/genetics | 2 | 4.0 |
Antibodies, Monoclonal/diagnostic use | 11 | 1.0 |
Cell Transformation, Neoplastic | 8 | 1.0 |
Endometrial Neoplasms/*genetics/pathology | 2 | 6.0 |
Hyperplasia | 20 | 5.0 |
Proliferating Cell Nuclear Antigen/biosynthesis | 32 | 68.0 |
Proto-Oncogene Proteins/*biosynthesis | 4 | 2.0 |
Cell Cycle Proteins/*chemistry/ultrastructure | 2 | 100.0 |
Disease Models, Animal | 9 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Immunohistochemistry/methods | 18 | 2.0 |
Protein p53/*metabolism | 32 | 5.0 |
Proliferating Cell Nuclear Antigen/isolation & purification | 2 | 66.0 |
Reproducibility of Results | 9 | 0.0 |
Tumor Markers, Biological/*isolation & purification | 2 | 33.0 |
Cell Count | 13 | 1.0 |
Proliferating Cell Nuclear Antigen/*analysis | 166 | 87.0 |
Genes, p53 | 24 | 5.0 |
Ki-67 Antigen/*analysis | 14 | 20.0 |
Pregnancy | 18 | 0.0 |
Pregnancy Trimester, First | 3 | 1.0 |
Sensitivity and Specificity | 16 | 0.0 |
Statistics, Nonparametric | 9 | 0.0 |
Apoptosis | 23 | 1.0 |
Mice, Inbred C3H | 2 | 0.0 |
*Muscle Proteins | 3 | 1.0 |
Protein p53/biosynthesis | 6 | 4.0 |
Tumor Virus Infections/metabolism/*pathology | 2 | 100.0 |
In Situ Hybridization | 18 | 0.0 |
In Situ Nick-End Labeling | 22 | 3.0 |
RNA, Viral/genetics | 2 | 2.0 |
Cyclin-Dependent Kinases/metabolism | 6 | 1.0 |
Cyclins/genetics/*metabolism | 5 | 6.0 |
DNA Fragmentation/drug effects | 2 | 2.0 |
Dose-Response Relationship, Drug | 15 | 0.0 |
Lung Neoplasms/genetics/*metabolism/pathology | 2 | 7.0 |
Mutation | 23 | 0.0 |
Protein p53/*genetics | 8 | 4.0 |
*Proto-Oncogene Proteins | 11 | 0.0 |
China/epidemiology | 3 | 1.0 |
Incidence | 3 | 0.0 |
Mice, SCID | 6 | 0.0 |
Brain Neoplasms/*pathology | 4 | 5.0 |
Mitosis | 12 | 2.0 |
S Phase | 19 | 5.0 |
DNA, Neoplasm/*analysis | 27 | 14.0 |
Proteins/analysis | 2 | 1.0 |
Carcinoma, Squamous Cell/chemically induced/*chemistry/pathology | 2 | 100.0 |
Staining and Labeling/methods | 5 | 4.0 |
Image Processing, Computer-Assisted | 14 | 3.0 |
Liver/*metabolism | 2 | 0.0 |
Nucleolus Organizer Region/*metabolism | 3 | 50.0 |
Ploidies | 40 | 15.0 |
Regression Analysis | 17 | 1.0 |
Antigens, CD44/*biosynthesis | 5 | 7.0 |
Carcinoma, Squamous Cell/diagnosis/*metabolism | 2 | 66.0 |
Glycoproteins/*biosynthesis | 2 | 4.0 |
Neoplasm Metastasis | 19 | 1.0 |
Neoplasm Proteins/*biosynthesis | 6 | 6.0 |
Tumor Markers, Biological/*biosynthesis | 10 | 12.0 |
Lymphatic Metastasis/*pathology | 2 | 5.0 |
Protein p53/metabolism | 28 | 4.0 |
Retinoblastoma Protein/metabolism | 8 | 2.0 |
Cyclins/biosynthesis | 7 | 7.0 |
Mice, Nude | 12 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 31 | 0.0 |
Microscopy, Fluorescence | 5 | 0.0 |
Mouth Neoplasms/*chemistry/*pathology | 2 | 66.0 |
Protein p53/*analysis | 50 | 27.0 |
Tumor Markers, Biological/analysis | 28 | 3.0 |
Breast Neoplasms/*diagnosis | 2 | 11.0 |
Disease-Free Survival | 23 | 2.0 |
Risk Assessment | 2 | 0.0 |
Genes, Tumor Suppressor | 6 | 0.0 |
Up-Regulation | 11 | 0.0 |
Carcinoma/*metabolism | 3 | 3.0 |
Colon/metabolism | 2 | 1.0 |
Colonic Neoplasms/*metabolism | 2 | 2.0 |
Cytosol/metabolism | 2 | 0.0 |
Liver/metabolism | 2 | 0.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
Evaluation Studies | 4 | 0.0 |
Proliferating Cell Nuclear Antigen/*diagnostic use | 2 | 100.0 |
Antigens, CD/analysis | 8 | 0.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 2 | 0.0 |
Autopsy | 4 | 2.0 |
DNA/*analysis | 5 | 2.0 |
DNA-Binding Proteins/metabolism | 13 | 0.0 |
Macromolecular Substances | 15 | 0.0 |
Proteins/chemistry/genetics/*metabolism | 3 | 3.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 2 | 1.0 |
Substrate Specificity | 6 | 0.0 |
Organ Size | 2 | 1.0 |
Parathyroid Glands/chemistry/*pathology | 3 | 60.0 |
Cell Cycle | 37 | 3.0 |
Chromatin/metabolism | 3 | 1.0 |
Cycloheximide/pharmacology | 3 | 0.0 |
DNA/*radiation effects | 2 | 7.0 |
*DNA Damage | 12 | 2.0 |
Fibroblasts/cytology/metabolism/radiation effects | 2 | 25.0 |
Fungal Proteins/metabolism | 4 | 2.0 |
G0 Phase | 2 | 2.0 |
G1 Phase | 6 | 1.0 |
Microscopy, Confocal | 3 | 0.0 |
Nuclear Proteins/metabolism | 13 | 1.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
*Helicobacter pylori | 2 | 1.0 |
Receptor, erbB-2/*analysis | 13 | 15.0 |
Bronchi/*pathology | 2 | 8.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Cyclin D1/analysis | 4 | 10.0 |
Biopsy, Needle | 13 | 3.0 |
Polymerase Chain Reaction | 23 | 0.0 |
Telomerase/*metabolism | 2 | 4.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Cyclins/*metabolism | 13 | 4.0 |
Phosphorylation | 13 | 0.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
DNA Fragmentation | 5 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 10 | 4.0 |
Hysterectomy | 2 | 2.0 |
Cell Differentiation/physiology | 5 | 1.0 |
Gene Expression/drug effects | 5 | 0.0 |
Mice, Inbred BALB C | 11 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 6 | 1.0 |
Chemotherapy, Adjuvant | 11 | 4.0 |
Receptor, erbB-2/metabolism | 8 | 4.0 |
Gestational Age | 3 | 0.0 |
Receptor, Epidermal Growth Factor/*metabolism | 8 | 1.0 |
Transforming Growth Factor alpha/*metabolism | 3 | 4.0 |
Uterine Neoplasms/*metabolism | 3 | 9.0 |
Genes, erbB-2 | 2 | 2.0 |
Medical Records | 2 | 2.0 |
DNA Primers/genetics | 5 | 0.0 |
DNA Replication/*physiology | 5 | 13.0 |
DNA-Directed DNA Polymerase/*metabolism | 10 | 38.0 |
Oligodeoxyribonucleotides/metabolism | 2 | 4.0 |
Proliferating Cell Nuclear Antigen/*biosynthesis/genetics | 3 | 100.0 |
*Transcription Factors | 2 | 0.0 |
Cohort Studies | 5 | 0.0 |
DNA, Neoplasm/*genetics | 4 | 1.0 |
Image Cytometry | 3 | 25.0 |
Papillomavirus, Human/*isolation & purification | 3 | 11.0 |
*Ploidies | 13 | 18.0 |
Carcinoma, Basal Cell/*pathology | 2 | 20.0 |
Diagnosis, Differential | 22 | 1.0 |
Skin Neoplasms/*pathology | 6 | 6.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 3 | 4.0 |
Carcinoma, Squamous Cell/*genetics/*pathology | 2 | 18.0 |
Proliferating Cell Nuclear Antigen/analysis/*biosynthesis | 8 | 100.0 |
Treatment Outcome | 19 | 0.0 |
Epithelium/metabolism/pathology | 3 | 4.0 |
Esophagus/metabolism/pathology | 2 | 28.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
Cell Division/drug effects/genetics | 2 | 2.0 |
Administration, Oral | 3 | 0.0 |
Epithelial Cells/metabolism/pathology | 3 | 6.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Proliferating Cell Nuclear Antigen/immunology/metabolism | 3 | 100.0 |
Chromosome Aberrations | 3 | 0.0 |
Follow-Up Studies | 43 | 1.0 |
Lymphatic Metastasis | 44 | 4.0 |
Breast Neoplasms/*chemistry/pathology | 7 | 11.0 |
Carcinoma, Ductal, Breast/*chemistry/pathology | 2 | 15.0 |
Cyclins/*analysis | 8 | 20.0 |
*Drosophila Proteins | 3 | 0.0 |
Neoplasm Proteins/*analysis | 42 | 12.0 |
Receptors, Estrogen/analysis | 11 | 3.0 |
Receptors, Progesterone/analysis | 11 | 4.0 |
Apoptosis/*physiology | 4 | 0.0 |
DNA Repair/physiology | 3 | 8.0 |
DNA Replication/physiology | 5 | 15.0 |
Fibroblasts/cytology | 4 | 1.0 |
Neovascularization, Pathologic/*pathology | 3 | 2.0 |
Proliferating Cell Nuclear Antigen/biosynthesis/genetics | 3 | 42.0 |
RNA, Messenger/metabolism | 10 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Receptors, Vascular Endothelial Growth Factor | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 5 | 3.0 |
Neoplasm Recurrence, Local/pathology | 4 | 7.0 |
Proliferating Cell Nuclear Antigen/*genetics | 13 | 81.0 |
Receptor, erbB-2/*genetics | 3 | 8.0 |
Risk Factors | 14 | 0.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
Cell Cycle Proteins/*genetics | 4 | 2.0 |
DNA Replication/genetics | 4 | 7.0 |
Genotype | 5 | 0.0 |
Phosphoproteins/genetics | 2 | 1.0 |
Ubiquitin-Conjugating Enzymes/*genetics | 2 | 66.0 |
Metaplasia | 6 | 6.0 |
Polymerase Chain Reaction/methods | 6 | 0.0 |
Receptor, Epidermal Growth Factor/metabolism | 4 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 3 | 0.0 |
Nucleolus Organizer Region/*ultrastructure | 12 | 60.0 |
Silver Staining | 24 | 29.0 |
Colorectal Neoplasms/*pathology | 6 | 10.0 |
Genetic Markers | 6 | 0.0 |
Diploidy | 7 | 6.0 |
Nucleolus Organizer Region/pathology | 5 | 62.0 |
Proliferating Cell Nuclear Antigen | 194 | 85.0 |
Cell Death | 2 | 0.0 |
Regeneration | 2 | 3.0 |
Antibody Specificity | 7 | 0.0 |
*Antigens, Nuclear | 2 | 1.0 |
*DNA Helicases | 3 | 1.0 |
CHO Cells | 6 | 0.0 |
Cricetulus | 3 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Fibroblasts | 8 | 1.0 |
Genes, Structural | 3 | 0.0 |
Genetic Complementation Test | 3 | 0.0 |
Hamsters | 11 | 0.0 |
Cell-Free System | 2 | 0.0 |
Consensus Sequence | 4 | 0.0 |
*DNA Glycosylases | 3 | 4.0 |
DNA Repair/*physiology | 3 | 2.0 |
DNA-(Apurinic or Apyrimidinic Site) Lyase | 3 | 4.0 |
DNA-Binding Proteins/physiology | 2 | 0.0 |
Deoxyribonuclease IV (Phage T4-Induced) | 3 | 6.0 |
Flap Endonucleases | 7 | 23.0 |
Models, Genetic | 2 | 0.0 |
Proliferating Cell Nuclear Antigen/*physiology | 3 | 100.0 |
DNA-Directed DNA Polymerase/metabolism | 8 | 24.0 |
Proliferating Cell Nuclear Antigen/chemistry/genetics/*metabolism | 6 | 85.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
Species Specificity | 6 | 0.0 |
Meningeal Neoplasms/*metabolism/pathology | 2 | 25.0 |
Meningioma/*metabolism/pathology | 2 | 11.0 |
Receptors, Androgen/*biosynthesis | 2 | 10.0 |
G1 Phase/*physiology | 3 | 6.0 |
G2 Phase/physiology | 2 | 7.0 |
Neoplasm Transplantation | 5 | 0.0 |
S Phase/physiology | 8 | 10.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Transplantation, Heterologous | 5 | 0.0 |
Lung Neoplasms/metabolism | 2 | 5.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
Oncogenes/*genetics | 2 | 2.0 |
P-Glycoprotein/analysis | 3 | 12.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis | 4 | 4.0 |
*Genes, p53 | 8 | 1.0 |
*Genes, ras | 2 | 0.0 |
DNA/biosynthesis | 9 | 1.0 |
DNA, Antisense/genetics | 2 | 4.0 |
Gene Expression Profiling | 4 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Microscopy, Electron, Scanning | 3 | 1.0 |
Gastric Mucosa/*pathology | 2 | 8.0 |
Discriminant Analysis | 3 | 3.0 |
Ki-67 Antigen/biosynthesis | 5 | 6.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 4 | 2.0 |
Adenocarcinoma/pathology | 4 | 4.0 |
Age Factors | 16 | 0.0 |
Sex Factors | 10 | 0.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
DNA, Viral/analysis | 6 | 1.0 |
Microcirculation/pathology | 3 | 3.0 |
Mitotic Index | 27 | 16.0 |
Neovascularization, Pathologic | 5 | 1.0 |
Papillomavirus, Human/genetics | 5 | 12.0 |
Culture Techniques | 4 | 0.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 2 | 0.0 |
Reference Values | 10 | 0.0 |
Cyclin D1/*metabolism | 2 | 3.0 |
Antigens, CD/metabolism | 2 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Transforming Growth Factor beta/metabolism | 3 | 1.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Magnetic Resonance Imaging | 4 | 0.0 |
Neoplasm Recurrence, Local | 20 | 4.0 |
Aneuploidy | 11 | 5.0 |
DNA, Neoplasm/genetics | 11 | 1.0 |
Carcinoma, Squamous Cell/metabolism/pathology | 3 | 7.0 |
Epithelial Cells/cytology | 3 | 4.0 |
Antibodies, Monoclonal/immunology | 8 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 2 | 2.0 |
Chickens | 5 | 0.0 |
Cross Reactions | 3 | 0.0 |
Pilot Projects | 5 | 0.0 |
Adenoviridae/genetics | 2 | 0.0 |
Apoptosis/genetics | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Rats, Inbred Lew | 2 | 0.0 |
DNA, Neoplasm/analysis | 19 | 2.0 |
Fluorescent Antibody Technique, Indirect | 7 | 0.0 |
Precancerous Conditions/*metabolism/pathology | 3 | 14.0 |
Retinoblastoma Protein/*metabolism | 2 | 1.0 |
Tumor Markers, Biological/metabolism | 10 | 2.0 |
Adenosinetriphosphatase/metabolism | 4 | 3.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Saccharomyces cerevisiae | 4 | 1.0 |
Carcinoma, Squamous Cell/pathology | 3 | 6.0 |
Dyes/diagnostic use | 6 | 7.0 |
Gelatinase A/analysis | 2 | 18.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Interstitial Collagenase/analysis | 2 | 28.0 |
*Neoplasm Recurrence, Local | 2 | 4.0 |
*Neovascularization, Pathologic | 2 | 0.0 |
Biological Markers/*analysis | 3 | 2.0 |
Chemoprevention | 3 | 7.0 |
Oncogenes | 3 | 1.0 |
Papillomavirus, Human | 2 | 5.0 |
Proliferating Cell Nuclear Antigen/*chemistry/metabolism | 3 | 75.0 |
Questionnaires | 2 | 0.0 |
Adenocarcinoma/*pathology/surgery | 2 | 18.0 |
Epithelium/immunology | 6 | 4.0 |
Antibodies/pharmacology | 2 | 0.0 |
Cell Cycle/physiology | 5 | 1.0 |
Proliferating Cell Nuclear Antigen/pharmacology | 2 | 66.0 |
Neovascularization, Pathologic/*metabolism | 2 | 1.0 |
Nuclear Proteins/biosynthesis | 3 | 6.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
*Chromosomal Proteins, Non-Histone | 2 | 0.0 |
Cyclin-Dependent Kinases/chemistry/metabolism | 2 | 40.0 |
Protein-Serine-Threonine Kinases/chemistry/metabolism | 2 | 20.0 |
Proteins/isolation & purification/metabolism | 2 | 18.0 |
Cell Nucleus/metabolism/pathology | 2 | 6.0 |
Karyotyping | 2 | 0.0 |
Neoplasm Proteins/biosynthesis | 2 | 2.0 |
*Nuclear Proteins | 8 | 0.0 |
Proto-Oncogene Proteins/biosynthesis | 6 | 3.0 |
Thymidine Phosphorylase/*metabolism | 2 | 8.0 |
Blotting, Southern | 4 | 0.0 |
Cell Line, Transformed | 10 | 0.0 |
Cell Transformation, Viral | 3 | 1.0 |
Proliferating Cell Nuclear Antigen/*chemistry/*metabolism | 2 | 66.0 |
Base Pair Mismatch | 3 | 1.0 |
DNA-Binding Proteins/*metabolism | 16 | 0.0 |
*Multidrug Resistance-Associated Proteins | 2 | 3.0 |
DNA/*biosynthesis | 4 | 4.0 |
Nuclear Proteins/*metabolism | 25 | 3.0 |
Proliferating Cell Nuclear Antigen/genetics/*metabolism | 6 | 66.0 |
Lymphoma, Non-Hodgkin/*immunology/pathology | 2 | 18.0 |
Nucleolus Organizer Region/chemistry | 4 | 80.0 |
Rabbits | 10 | 0.0 |
*Electrophoresis, Gel, Two-Dimensional | 2 | 25.0 |
Neoplasm Proteins/*biosynthesis/genetics | 2 | 1.0 |
*Accidents, Radiation | 3 | 14.0 |
*Power Plants | 2 | 13.0 |
Ukraine | 3 | 11.0 |
Cyclin E/analysis | 2 | 13.0 |
Apoptosis/*genetics | 5 | 2.0 |
Genes, bcl-2 | 5 | 4.0 |
Genes, p53/*genetics | 9 | 2.0 |
Recombinant Proteins/genetics/isolation & purification/metabolism | 2 | 2.0 |
*Gene Expression Regulation, Leukemic | 2 | 2.0 |
Adenoma/*pathology | 4 | 18.0 |
Staining and Labeling | 33 | 5.0 |
Gastroscopy | 2 | 4.0 |
Stomach Neoplasms/*genetics/pathology/surgery | 2 | 25.0 |
Cell Nucleus/pathology | 4 | 5.0 |
Nucleolus Organizer Region/*pathology | 9 | 69.0 |
Cyclin A/analysis | 4 | 33.0 |
Prostate-Specific Antigen/analysis | 2 | 4.0 |
*Cell Division | 13 | 7.0 |
Cervix Neoplasms/*pathology | 2 | 9.0 |
Dogs | 3 | 0.0 |
Mutagenesis, Site-Directed | 10 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
Bromodeoxyuridine/metabolism | 2 | 2.0 |
Epidermal Growth Factor/pharmacology | 5 | 0.0 |
Insulin/pharmacology | 3 | 1.0 |
*Bile Ducts, Intrahepatic | 2 | 6.0 |
Carcinoma, Hepatocellular/*etiology | 2 | 22.0 |
Hepatitis B Surface Antigens/analysis | 2 | 3.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Proto-Oncogenes | 2 | 1.0 |
Cytoplasm/ultrastructure | 5 | 7.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
DNA-Binding Proteins/*chemistry/metabolism | 2 | 2.0 |
*Homeodomain Proteins | 24 | 8.0 |
Protein Conformation | 15 | 0.0 |
*Proto-Oncogene Proteins c-bcl-2 | 22 | 4.0 |
*Repressor Proteins | 26 | 2.0 |
Carcinoma, Squamous Cell/*pathology | 6 | 7.0 |
Cell Differentiation/drug effects | 5 | 0.0 |
Esophageal Neoplasms/*pathology | 4 | 22.0 |
Genetic Vectors | 3 | 0.0 |
Chromatography, Gel | 3 | 0.0 |
DNA/biosynthesis/metabolism | 3 | 25.0 |
DNA Polymerase III/metabolism | 4 | 36.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Dimerization | 3 | 0.0 |
Thymus Gland/metabolism | 2 | 2.0 |
Chi-Square Distribution | 3 | 0.0 |
Carbon-Oxygen Lyases/*metabolism | 2 | 10.0 |
Conserved Sequence | 4 | 0.0 |
Ki-67 Antigen/*metabolism | 13 | 27.0 |
Proliferating Cell Nuclear Antigen/*immunology | 9 | 90.0 |
Adenocarcinoma/metabolism/pathology | 2 | 3.0 |
Carcinoma, Non-Small-Cell Lung/*metabolism/pathology | 2 | 8.0 |
Cyclins/*biosynthesis | 6 | 11.0 |
Lung Neoplasms/*metabolism/pathology | 3 | 4.0 |
Antigens, CD95/*metabolism | 3 | 2.0 |
Epithelium/drug effects/metabolism | 2 | 3.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 2 | 2.0 |
Organ Size/drug effects | 2 | 2.0 |
Rats, Wistar | 12 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 4 | 0.0 |
DNA/*genetics | 2 | 0.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Adenocarcinoma/metabolism | 2 | 2.0 |
Cyclin D1/*biosynthesis | 2 | 10.0 |
Cisplatin/administration & dosage | 5 | 2.0 |
Combined Modality Therapy | 13 | 1.0 |
Bone Marrow/chemistry | 2 | 6.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors | 4 | 5.0 |
*Mitosis | 4 | 3.0 |
Peptide Mapping | 2 | 0.0 |
Point Mutation | 7 | 0.0 |
*Mitotic Index | 5 | 50.0 |
*Nucleolus Organizer Region | 5 | 62.0 |
*Proliferating Cell Nuclear Antigen | 4 | 80.0 |
*Cloning, Molecular | 2 | 0.0 |
Proliferating Cell Nuclear Antigen/chemistry/*genetics/*metabolism | 2 | 100.0 |
Sequence Analysis, DNA | 4 | 0.0 |
DNA/*metabolism | 6 | 1.0 |
Intestinal Mucosa/metabolism | 2 | 1.0 |
Spain/epidemiology | 2 | 1.0 |
Estradiol/*analogs & derivatives/*pharmacology | 3 | 15.0 |
Rats, Inbred F344 | 5 | 1.0 |
Cell Division/genetics | 6 | 1.0 |
DNA/analysis | 5 | 0.0 |
*Diploidy | 2 | 9.0 |
Infant, Newborn | 7 | 0.0 |
Autoantibodies/*biosynthesis | 2 | 3.0 |
Autoantigens/*immunology | 5 | 3.0 |
Longitudinal Studies | 3 | 0.0 |
Lupus Erythematosus, Systemic/*immunology | 4 | 2.0 |
*Cell Cycle Proteins | 9 | 0.0 |
Cyclins/analysis | 5 | 11.0 |
Herpesvirus 4, Human/isolation & purification | 2 | 3.0 |
Microtubule-Associated Proteins/analysis | 2 | 5.0 |
Remission Induction | 4 | 0.0 |
Retinoblastoma Protein/analysis | 2 | 5.0 |
Viral Matrix Proteins/analysis | 2 | 14.0 |
DNA Ligases/metabolism | 5 | 15.0 |
Surface Plasmon Resonance | 2 | 1.0 |
Premenopause | 3 | 3.0 |
Loss of Heterozygosity | 2 | 0.0 |
Antigens, CD44/analysis | 4 | 5.0 |
Cathepsin D/analysis | 2 | 5.0 |
Epithelium/pathology | 11 | 8.0 |
Fibronectins/analysis | 2 | 3.0 |
Myocardium/pathology | 2 | 2.0 |
Ovarian Neoplasms/*chemistry/pathology | 2 | 15.0 |
Carcinoma, Transitional Cell/*chemistry/pathology | 2 | 28.0 |
Cell Nucleus/chemistry | 9 | 4.0 |
Fixatives | 8 | 10.0 |
Formaldehyde | 12 | 12.0 |
Radiotherapy, Adjuvant | 6 | 6.0 |
Bromodeoxyuridine/analysis | 3 | 42.0 |
Cell Division/*physiology | 5 | 2.0 |
Colonic Neoplasms/pathology | 2 | 3.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
HL-60 Cells | 2 | 0.0 |
Carcinoma, Mucoepidermoid/*metabolism/pathology | 2 | 100.0 |
Salivary Gland Neoplasms/*metabolism/pathology | 2 | 28.0 |
Forecasting | 3 | 0.0 |
Brain/pathology | 6 | 1.0 |
Cell Division/*genetics | 2 | 3.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Carcinoma, Basal Cell/*metabolism/pathology | 2 | 20.0 |
Skin Neoplasms/*metabolism/pathology | 2 | 3.0 |
Epithelium/chemistry/pathology | 4 | 11.0 |
*Gene Expression | 6 | 0.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
Life Tables | 5 | 2.0 |
Aging/pathology | 2 | 11.0 |
Histological Techniques | 3 | 6.0 |
Protein p53/*analysis/genetics | 5 | 23.0 |
Coronary Angiography | 2 | 0.0 |
Muscle, Smooth, Vascular/metabolism/pathology | 3 | 16.0 |
Recurrence | 9 | 0.0 |
*Stents | 3 | 4.0 |
Endodeoxyribonucleases/*metabolism | 3 | 17.0 |
Proliferating Cell Nuclear Antigen/*pharmacology | 2 | 100.0 |
Templates, Genetic | 5 | 3.0 |
Receptor, erbB-2/*biosynthesis | 5 | 10.0 |
Colorectal Neoplasms/*metabolism/pathology | 2 | 4.0 |
Ki-67 Antigen/*genetics | 2 | 33.0 |
Treatment Failure | 4 | 1.0 |
Tumor Markers, Biological/*genetics | 3 | 2.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
Hepatectomy | 3 | 4.0 |
*Mutation | 7 | 0.0 |
Antigens, CD44/metabolism | 2 | 2.0 |
Cathepsin D/metabolism | 2 | 5.0 |
Colorectal Neoplasms/diagnosis/*metabolism | 2 | 100.0 |
Ki-67 Antigen/metabolism | 12 | 5.0 |
Cell Cycle/drug effects/radiation effects | 2 | 10.0 |
DNA Damage/*radiation effects | 2 | 18.0 |
Proto-Oncogene Proteins c-fos/*metabolism | 2 | 5.0 |
Ovarian Follicle/*physiology | 2 | 8.0 |
Cell Extracts | 2 | 1.0 |
DNA Damage/*genetics | 3 | 5.0 |
Abortifacient Agents, Steroidal/*pharmacology | 2 | 50.0 |
Apoptosis/*drug effects | 9 | 1.0 |
Mifepristone/*pharmacology | 2 | 8.0 |
Cyclin-Dependent Kinases/*biosynthesis | 3 | 9.0 |
Protein p16/*biosynthesis | 2 | 12.0 |
Receptor, erbB-2/analysis | 10 | 10.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Protein p53/genetics | 6 | 3.0 |
Proto-Oncogene Protein p21(ras)/genetics | 2 | 13.0 |
Proto-Oncogene Proteins/genetics | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 2 | 1.0 |
Cell Nucleus/ultrastructure | 11 | 9.0 |
Nuclear Proteins/*analysis | 105 | 59.0 |
Proto-Oncogene Proteins/*analysis | 4 | 2.0 |
Silver/diagnostic use | 3 | 42.0 |
Cell Nucleus/metabolism/radiation effects | 2 | 33.0 |
Prostatic Hyperplasia/*metabolism/pathology | 2 | 6.0 |
DNA Polymerase I/*metabolism | 2 | 50.0 |
DNA Primase/metabolism | 4 | 80.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Antibodies, Monoclonal/analysis | 5 | 6.0 |
*DNA Topoisomerases, Type II, Eukaryotic | 3 | 15.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Binding Sites/genetics | 4 | 0.0 |
DNA-Binding Proteins/chemistry/genetics/*metabolism | 3 | 1.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Proliferating Cell Nuclear Antigen/*blood | 4 | 100.0 |
Factor VIII/analysis | 3 | 2.0 |
Lymph Nodes/*pathology | 3 | 3.0 |
Irrigation | 2 | 3.0 |
Base Pair Mismatch/*genetics | 2 | 3.0 |
DNA Repair/*genetics | 2 | 0.0 |
Hydrolysis | 3 | 0.0 |
Breast Neoplasms/*metabolism/*pathology | 2 | 5.0 |
Cell Line, Tumor | 8 | 0.0 |
Neovascularization, Pathologic/drug therapy | 2 | 7.0 |
Xenograft Model Antitumor Assays | 2 | 0.0 |
Antigens, Neoplasm/*metabolism | 7 | 7.0 |
Brain Neoplasms/*metabolism/pathology | 3 | 6.0 |
Mutation/genetics | 6 | 0.0 |
Transforming Growth Factor alpha/metabolism | 2 | 2.0 |
DNA Topoisomerases, Type I/*metabolism | 2 | 7.0 |
*Replication Origin | 2 | 11.0 |
Sequence Deletion | 10 | 0.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
Cyclins/*genetics | 4 | 2.0 |
Lymph Nodes/pathology | 6 | 2.0 |
Binding, Competitive | 6 | 0.0 |
DNA, Single-Stranded/metabolism | 3 | 4.0 |
Fluorescent Antibody Technique | 17 | 0.0 |
Gene Library | 2 | 0.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Protein p53/genetics/*metabolism | 2 | 1.0 |
Antigens, CD44/*analysis | 2 | 1.0 |
Cell Cycle Proteins/*metabolism | 6 | 1.0 |
Probability | 4 | 0.0 |
Cell Cycle/*physiology | 5 | 1.0 |
Observer Variation | 5 | 4.0 |
Adenoma/genetics/*metabolism/pathology | 2 | 28.0 |
RNA, Messenger | 3 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Arthritis, Rheumatoid/immunology | 2 | 2.0 |
Enzyme-Linked Immunosorbent Assay | 9 | 0.0 |
Lupus Erythematosus, Systemic/immunology | 4 | 3.0 |
Sjogren's Syndrome/immunology | 3 | 17.0 |
*Carrier Proteins | 5 | 0.0 |
Exons | 3 | 0.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
*Gene Expression Regulation | 4 | 0.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Transcription Factors/*metabolism | 7 | 0.0 |
*Transcription, Genetic | 7 | 0.0 |
Microfilament Proteins/analysis | 2 | 11.0 |
Cell Fractionation | 2 | 0.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 5 | 7.0 |
Liver Neoplasms/*metabolism/pathology | 6 | 8.0 |
RNA, Messenger/genetics | 7 | 0.0 |
Cell Transformation, Neoplastic/genetics/*pathology | 2 | 18.0 |
Ki-67 Antigen/genetics | 4 | 44.0 |
Larynx/pathology | 2 | 16.0 |
Oncogene Proteins/genetics | 2 | 2.0 |
Tumor Markers, Biological/*analysis/genetics | 4 | 11.0 |
3T3 Cells | 6 | 0.0 |
Mutagenesis | 5 | 0.0 |
Proteasome Endopeptidase Complex | 3 | 0.0 |
Ubiquitins/*metabolism | 2 | 1.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 7 | 8.0 |
Laryngeal Neoplasms/*metabolism/pathology | 2 | 20.0 |
*Cell Cycle | 7 | 3.0 |
Ampulla of Vater/*pathology/surgery | 2 | 100.0 |
Cell Transformation, Neoplastic/pathology | 4 | 9.0 |
Papillomavirus, Human/*genetics | 2 | 2.0 |
Adenocarcinoma/*genetics/pathology | 2 | 2.0 |
Genes, erbB-2/genetics | 2 | 7.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Enzyme Inhibitors/*pharmacology | 3 | 0.0 |
*S Phase | 11 | 16.0 |
*Tumor Markers, Biological | 5 | 2.0 |
Esophagectomy | 2 | 14.0 |
Cell Cycle/genetics | 5 | 3.0 |
Gene Expression Regulation | 9 | 0.0 |
Genes, Tumor Suppressor/genetics | 2 | 1.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Odontogenic Cysts/genetics/*pathology | 2 | 100.0 |
Oncogene Proteins/*genetics | 2 | 1.0 |
Proliferating Cell Nuclear Antigen/analysis/genetics | 2 | 50.0 |
Protein p53/analysis/genetics | 3 | 13.0 |
Carcinoma, Hepatocellular/*pathology | 3 | 6.0 |
Liver Neoplasms/*pathology | 2 | 3.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
Cell Survival/drug effects | 3 | 0.0 |
Cyclin A/biosynthesis | 2 | 14.0 |
Flow Cytometry/methods | 5 | 1.0 |
K562 Cells | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/genetics | 3 | 5.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Breast Neoplasms/immunology/*pathology | 4 | 22.0 |
Doxorubicin/administration & dosage | 4 | 2.0 |
Infusions, Intravenous | 2 | 0.0 |
Stomach Neoplasms/metabolism/*pathology | 3 | 9.0 |
Insulin/*physiology | 2 | 4.0 |
Liver Regeneration/*drug effects | 2 | 22.0 |
Nephrectomy | 3 | 3.0 |
Bladder Neoplasms/*metabolism/pathology | 5 | 15.0 |
Carcinoma, Transitional Cell/*metabolism/pathology | 5 | 29.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Multienzyme Complexes/*metabolism | 3 | 2.0 |
Immunophenotyping | 9 | 0.0 |
*Lymphocyte Activation | 2 | 0.0 |
Keratin/metabolism | 3 | 2.0 |
Parathyroid Hormone-Related Protein | 2 | 2.0 |
Platelet-Derived Growth Factor/metabolism | 2 | 3.0 |
Proteins/metabolism | 3 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 5 | 1.0 |
Oncogene Proteins/analysis | 2 | 18.0 |
Radiotherapy Dosage | 3 | 2.0 |
*Ultraviolet Rays | 4 | 1.0 |
Exodeoxyribonuclease V | 4 | 12.0 |
Genes, bcl-2/genetics | 2 | 5.0 |
Genes, p53/genetics | 7 | 3.0 |
Stomach Neoplasms/*metabolism/pathology | 3 | 5.0 |
Breast Neoplasms/genetics/*metabolism/pathology | 2 | 4.0 |
Protein p53/genetics/metabolism | 3 | 3.0 |
Kidney Neoplasms/*pathology | 2 | 6.0 |
Adenocarcinoma/chemistry/*mortality | 2 | 100.0 |
Cyclin B/*analysis | 2 | 66.0 |
Lymph Node Excision | 3 | 4.0 |
Vimentin/analysis | 6 | 2.0 |
Protein Biosynthesis | 5 | 0.0 |
*Proteins | 2 | 0.0 |
Breast Neoplasms/*metabolism/pathology | 3 | 1.0 |
Protein p53/analysis/*biosynthesis | 4 | 18.0 |
Severity of Illness Index | 2 | 0.0 |
Carcinoma, Hepatocellular/*chemistry/pathology | 2 | 28.0 |
Liver Neoplasms/*chemistry/pathology | 2 | 28.0 |
Kidney/metabolism | 2 | 0.0 |
Plasmids | 11 | 0.0 |
Transcription Factors/biosynthesis | 2 | 2.0 |
Carcinoma/*pathology | 3 | 5.0 |
Thyroid Neoplasms/*pathology | 2 | 10.0 |
Cisplatin/*pharmacology | 3 | 2.0 |
Cell Aging | 2 | 2.0 |
Cell Division/radiation effects | 3 | 6.0 |
DNA, Neoplasm/*metabolism | 2 | 6.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Gene Amplification | 5 | 0.0 |
Genes, myc | 2 | 0.0 |
Genes, Retinoblastoma | 3 | 3.0 |
Necrosis | 5 | 1.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors | 2 | 4.0 |
Proliferating Cell Nuclear Antigen/isolation & purification/*metabolism | 2 | 66.0 |
Cadherins/analysis | 2 | 6.0 |
Cell Nucleus/genetics | 2 | 6.0 |
Gene Expression/genetics | 4 | 1.0 |
Proliferating Cell Nuclear Antigen/*analysis/metabolism | 4 | 100.0 |
Fluorouracil/administration & dosage | 3 | 2.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 3 | 1.0 |
Glutathione Transferase/*metabolism | 2 | 6.0 |
Mitomycin/administration & dosage | 2 | 5.0 |
Carcinoma, Squamous Cell/genetics/*pathology | 3 | 17.0 |
Microwaves | 6 | 26.0 |
Proliferating Cell Nuclear Antigen/*analysis/genetics | 4 | 66.0 |
Tissue Fixation | 13 | 13.0 |
Endometrial Neoplasms/*chemistry/mortality/pathology | 2 | 50.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Cell Division/immunology | 5 | 1.0 |
Thymidine/metabolism | 4 | 1.0 |
Rats, Inbred Strains | 2 | 0.0 |
Image Processing, Computer-Assisted/*methods | 4 | 16.0 |
*Immunoenzyme Techniques | 6 | 4.0 |
Transforming Growth Factor alpha/*biosynthesis | 2 | 9.0 |
Proliferating Cell Nuclear Antigen/immunology/*metabolism | 4 | 100.0 |
Protein p53/immunology/*metabolism | 3 | 37.0 |
*Conserved Sequence | 2 | 1.0 |
Adenoma/genetics/*pathology | 2 | 25.0 |
Proliferating Cell Nuclear Antigen/*analysis/biosynthesis | 2 | 66.0 |
Protein p53/*analysis/biosynthesis | 2 | 33.0 |
Receptor, Epidermal Growth Factor/genetics | 4 | 3.0 |
Trans-Activation (Genetics) | 6 | 0.0 |
Genes, myc/genetics | 3 | 3.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Adenovirus E1A Proteins/*metabolism | 3 | 10.0 |
Antibodies, Neoplasm/analysis | 3 | 10.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
*Genes, myc | 2 | 0.0 |
Lung Neoplasms/*genetics/pathology | 2 | 2.0 |
Kidney Function Tests | 2 | 1.0 |
Recombinant Fusion Proteins/metabolism | 6 | 0.0 |
Protein-Serine-Threonine Kinases/*biosynthesis | 2 | 6.0 |
Carcinoma, Squamous Cell/*immunology/pathology | 2 | 14.0 |
Carcinoma/*metabolism/pathology | 3 | 4.0 |
Light | 2 | 0.0 |
Transcription, Genetic/radiation effects | 2 | 10.0 |
Nephroblastoma/metabolism/*pathology | 2 | 40.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Coculture Techniques | 2 | 0.0 |
Nucleolus Organizer Region | 2 | 50.0 |
Cell Nucleolus/ultrastructure | 2 | 33.0 |
Antigens, CD15/analysis | 2 | 7.0 |
Cell Nucleus/chemistry/pathology | 2 | 25.0 |
*Image Processing, Computer-Assisted | 2 | 4.0 |
Keratin/analysis | 5 | 2.0 |
Antigens, Neoplasm/metabolism | 3 | 4.0 |
Keratin/genetics | 2 | 4.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Atrophy | 3 | 2.0 |
Spermatogenesis/physiology | 2 | 6.0 |
Bone Marrow Examination | 2 | 5.0 |
Hematopoiesis/*drug effects | 2 | 2.0 |
Carcinoma, Squamous Cell/*genetics/metabolism | 2 | 7.0 |
Mouth Neoplasms/*genetics/metabolism | 2 | 33.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 2 | 4.0 |
Receptors, Estrogen/*metabolism | 4 | 1.0 |
Receptors, Progesterone/*metabolism | 2 | 1.0 |
Carcinoma, Squamous Cell/metabolism | 2 | 3.0 |
Lewis Blood-Group System/*metabolism | 2 | 25.0 |
*Formaldehyde | 2 | 16.0 |
Cell Cycle/radiation effects | 2 | 7.0 |
Enzyme Inhibitors | 2 | 2.0 |
Gene Expression Regulation/*radiation effects | 2 | 7.0 |
Skin | 3 | 4.0 |
Gene Expression Regulation, Neoplastic/drug effects | 5 | 1.0 |
Fibroblasts/pathology | 2 | 2.0 |
Macrophages/pathology | 2 | 1.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Mitosis/genetics/physiology | 2 | 28.0 |
Paraffin Embedding | 18 | 7.0 |
Macaca fascicularis | 2 | 0.0 |
Cell Proliferation/drug effects | 2 | 2.0 |
Fibroblasts/cytology/*metabolism | 3 | 8.0 |
Gene Expression Regulation, Neoplastic/*genetics | 3 | 1.0 |
Oligonucleotide Probes | 2 | 0.0 |
Oncogene Proteins, Viral/*genetics | 2 | 3.0 |
Protein Kinases/metabolism | 2 | 0.0 |
Receptor, Epidermal Growth Factor/analysis | 10 | 5.0 |
Nuclear Proteins | 4 | 9.0 |
Protein p53 | 2 | 8.0 |
Buffers | 2 | 1.0 |
Solutions | 2 | 1.0 |
Carcinoma/*chemistry/pathology | 5 | 31.0 |
Receptor, Epidermal Growth Factor/*analysis | 8 | 2.0 |
DNA Mutational Analysis | 4 | 0.0 |
Nuclear Proteins/*genetics | 8 | 1.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Eye Neoplasms/*metabolism/pathology | 2 | 66.0 |
Neoplasm Proteins/metabolism | 10 | 2.0 |
Fibroblasts/radiation effects | 2 | 7.0 |
Ovary/pathology | 2 | 6.0 |
Tumor Markers, Biological/genetics/*metabolism | 2 | 5.0 |
Chromatography, Affinity | 3 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
*Monomeric GTP-Binding Proteins | 4 | 8.0 |
*Nucleoside-Diphosphate Kinase | 7 | 10.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
Kidney Pelvis | 2 | 33.0 |
*Cell Differentiation | 2 | 0.0 |
Organ Culture Techniques | 3 | 0.0 |
*Immunohistochemistry | 2 | 2.0 |
Stromal Cells/pathology | 3 | 5.0 |
*Flow Cytometry | 5 | 3.0 |
Antineoplastic Agents/*pharmacology | 6 | 0.0 |
Cyclins/chemistry/*metabolism | 3 | 30.0 |
Cell Culture Techniques/methods | 2 | 0.0 |
Epithelial Cells | 9 | 1.0 |
Proto-Oncogene Proteins c-myc/analysis | 2 | 11.0 |
Catalysis | 3 | 0.0 |
DNA Polymerase III | 15 | 60.0 |
DNA, Circular/metabolism | 4 | 40.0 |
Molecular Weight | 9 | 0.0 |
Cyclin D1 | 10 | 7.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Stomach Neoplasms/*genetics/mortality/pathology | 2 | 33.0 |
Arthritis, Rheumatoid/*pathology | 2 | 10.0 |
Brain Neoplasms/mortality/*pathology | 2 | 40.0 |
Bromodeoxyuridine/*metabolism | 2 | 40.0 |
Cell Survival | 6 | 0.0 |
Mammals | 2 | 0.0 |
Bladder Neoplasms/*pathology | 2 | 9.0 |
Gastric Mucosa/*metabolism | 2 | 6.0 |
DNA Polymerase II | 3 | 50.0 |
G1 Phase/*drug effects | 2 | 2.0 |
Immunosuppressive Agents/*pharmacology | 2 | 0.0 |
Oncogene Proteins/metabolism | 2 | 2.0 |
Chromogranins/*analysis | 2 | 5.0 |
Cell Adhesion Molecules/analysis | 2 | 1.0 |
Carcinoma, Squamous Cell/*immunology | 2 | 7.0 |
Preoperative Care | 5 | 3.0 |
Epithelium/chemistry | 2 | 1.0 |
Prostatic Neoplasms/*chemistry/pathology | 2 | 9.0 |
*Genes, bcl-2 | 2 | 3.0 |
T-Lymphocytes/immunology | 3 | 0.0 |
Myelodysplastic Syndromes/*pathology | 2 | 6.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
G1 Phase/physiology | 3 | 4.0 |
Histocytochemistry | 3 | 0.0 |
Tumor Markers, Biological/*immunology | 2 | 8.0 |
Proliferating Cell Nuclear Antigen/analysis/metabolism | 2 | 50.0 |
Neoplasm, Residual | 3 | 3.0 |
Epithelium/metabolism | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 4 | 0.0 |
Insulin-Like Growth Factor I/*pharmacology | 2 | 1.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
DNA Repair/radiation effects | 2 | 15.0 |
Gamma Rays | 2 | 0.0 |
Colorectal Neoplasms/*chemistry/*pathology | 2 | 25.0 |
Proto-Oncogene Proteins c-myc/*analysis | 2 | 15.0 |
Antigens, Neoplasm/*analysis | 53 | 13.0 |
Detergents | 2 | 1.0 |
Transcription Factors/*analysis | 2 | 3.0 |
DNA/radiation effects | 2 | 7.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Mouth Mucosa/chemistry/pathology | 2 | 33.0 |
Adenocarcinoma/*chemistry/pathology | 4 | 9.0 |
Salivary Gland Neoplasms/*chemistry/pathology | 2 | 33.0 |
Lung Neoplasms/pathology | 3 | 5.0 |
Carcinoma, Papillary/genetics/*metabolism/pathology | 2 | 50.0 |
Immunohistochemistry/*methods | 6 | 6.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Antigens, Neoplasm/*biosynthesis | 2 | 6.0 |
Endometrial Neoplasms/*chemistry/pathology | 2 | 18.0 |
Autoantibodies/immunology | 2 | 1.0 |
Immunoglobulin G | 2 | 1.0 |
Keratoacanthoma/*pathology | 2 | 50.0 |
Skin Diseases/*pathology | 3 | 12.0 |
Nuclear Proteins/genetics | 3 | 1.0 |
Prostatic Neoplasms | 2 | 3.0 |
*Spermatogenesis | 2 | 6.0 |
Ovarian Neoplasms/chemistry/*pathology | 2 | 22.0 |
Arm | 2 | 6.0 |
Epidermis/pathology | 2 | 6.0 |
Keratosis/*pathology | 2 | 50.0 |
Breast/pathology | 2 | 6.0 |
Protein Structure, Secondary | 2 | 0.0 |
Glioblastoma/pathology | 2 | 11.0 |
Protein p53/*analysis/immunology | 2 | 33.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 2 | 1.0 |
Immunologic Techniques | 2 | 0.0 |
Endothelial Growth Factors/*analysis | 2 | 1.0 |
Lymphokines/*analysis | 2 | 1.0 |
Proliferating Cell Nuclear Antigen/*analysis/biosynthesis/genetics | 2 | 100.0 |
Antigens/*analysis | 4 | 4.0 |
Flow Cytometry/*methods | 4 | 1.0 |
Hyperplasia/pathology | 5 | 15.0 |
Mouth Neoplasms/*immunology/pathology | 2 | 66.0 |
Proliferating Cell Nuclear Antigen/*isolation & purification | 3 | 100.0 |
Laryngeal Neoplasms/immunology/*pathology | 2 | 50.0 |
Precancerous Conditions/immunology/*pathology | 3 | 100.0 |
Ovarian Neoplasms/*metabolism/pathology | 2 | 3.0 |
Lymphoma, Non-Hodgkin/immunology/*pathology | 2 | 25.0 |
DNA Probes, HPV | 2 | 10.0 |
Endothelium, Vascular/chemistry | 2 | 3.0 |
Biopsy, Fine-Needle | 2 | 10.0 |
Papilloma/*metabolism/pathology | 2 | 33.0 |
Lymphocytes/cytology | 2 | 2.0 |
Adenocarcinoma | 2 | 1.0 |
Ultraviolet Rays/*adverse effects | 2 | 4.0 |
Xeroderma Pigmentosum | 2 | 13.0 |
Autoantibodies/*immunology | 3 | 1.0 |
Connective Tissue Diseases/*immunology | 2 | 15.0 |
Nuclear Proteins/*immunology | 7 | 33.0 |
Laryngeal Neoplasms/*immunology | 2 | 22.0 |
Adenoma/*metabolism | 2 | 3.0 |
Colorectal Neoplasms/chemistry/*pathology | 2 | 20.0 |
Skin Neoplasms/*immunology/pathology | 2 | 10.0 |
Cell Fusion | 2 | 0.0 |
Interphase | 3 | 1.0 |
Bromodeoxyuridine/*analysis | 4 | 80.0 |
Carcinoma/immunology/*pathology | 2 | 28.0 |
Keratinocytes/pathology | 4 | 16.0 |
Prostate/*pathology | 2 | 8.0 |
Prostatic Hyperplasia/*pathology | 2 | 10.0 |
Precancerous Conditions/*pathology | 4 | 14.0 |
Prostatic Neoplasms/*metabolism/pathology | 3 | 3.0 |
S-Phase Kinase-Associated Proteins | 2 | 2.0 |
X-Rays | 3 | 2.0 |
Proliferating Cell Nuclear Antigen/drug effects/*metabolism | 3 | 75.0 |
Mouth Mucosa/metabolism | 2 | 11.0 |
Liver/*immunology | 2 | 5.0 |
Proto-Oncogene Proteins c-bcl-2 | 6 | 3.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
*Paraffin Embedding | 3 | 23.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Colorectal Neoplasms/immunology/*pathology | 2 | 66.0 |
S Phase/*physiology | 2 | 4.0 |
Bromodeoxyuridine | 3 | 9.0 |
Histidine | 2 | 4.0 |
Double-Blind Method | 2 | 0.0 |
*Lymphatic Metastasis | 4 | 10.0 |
Neck | 2 | 3.0 |
Neoplasm Proteins/*immunology | 2 | 5.0 |
Cytoskeletal Proteins/analysis | 2 | 4.0 |
Melanocytes/pathology | 2 | 11.0 |
Adenocarcinoma/*chemistry/mortality/pathology | 2 | 25.0 |
Carcinoma, Squamous Cell/chemistry/pathology | 2 | 18.0 |
S100 Proteins/analysis | 5 | 2.0 |
Nucleolus Organizer Region/ultrastructure | 2 | 50.0 |
Stomach Neoplasms/pathology | 3 | 13.0 |
Cyclins/*pharmacology | 2 | 18.0 |
Protein Kinase Inhibitors | 2 | 1.0 |
Antibodies, Monoclonal/*analysis/immunology | 2 | 50.0 |
Mesocricetus | 2 | 1.0 |
Neoplasm Proteins/*analysis/immunology | 2 | 11.0 |
Nuclear Proteins/*analysis/immunology | 3 | 30.0 |
Proliferating Cell Nuclear Antigen/*analysis/immunology | 2 | 66.0 |
*Epitopes | 2 | 1.0 |
Carcinoma, Squamous Cell/*chemistry/pathology | 3 | 13.0 |
Mouth Neoplasms/*chemistry/pathology | 2 | 22.0 |
Precancerous Conditions/pathology | 2 | 9.0 |
Skin Neoplasms/chemistry/*pathology | 2 | 4.0 |
Neoplasm Recurrence, Local/*pathology/surgery | 2 | 100.0 |
Transforming Growth Factor alpha/*analysis | 2 | 3.0 |
Glial Fibrillary Acidic Protein/analysis | 2 | 1.0 |
Kidney Neoplasms/*chemistry/*pathology | 2 | 66.0 |
Cercopithecus aethiops | 3 | 0.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
DNA Replication/drug effects | 2 | 1.0 |
Haplorhini | 2 | 0.0 |
Simian virus 40/genetics | 2 | 1.0 |
Xenopus | 2 | 0.0 |
HLA-DR Antigens/analysis | 2 | 0.0 |
Heat | 2 | 0.0 |
Lymphocyte Activation | 4 | 0.0 |
Cell Nucleus/immunology | 3 | 13.0 |
Breast Neoplasms/*chemistry/immunology/pathology | 2 | 66.0 |
Antigens, CD34 | 3 | 0.0 |
Membrane Glycoproteins/analysis | 3 | 1.0 |
Carcinoma/metabolism/secondary | 2 | 50.0 |
Carcinoma in Situ/chemistry | 2 | 33.0 |
Adenoma/*immunology | 2 | 28.0 |
Age of Onset | 2 | 0.0 |
Antibodies | 6 | 1.0 |
Astrocytes/pathology | 2 | 5.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Brain Neoplasms/*immunology/pathology | 3 | 50.0 |
Cell Cycle/immunology | 2 | 6.0 |
DNA/genetics | 2 | 0.0 |
Lung Neoplasms/*pathology | 2 | 2.0 |
Autoantigens/*analysis | 6 | 28.0 |
Cell Nucleus/*ultrastructure | 2 | 10.0 |
Fetus | 3 | 0.0 |
Heart/embryology | 2 | 3.0 |
Oncogenes/genetics | 2 | 2.0 |
Skin Neoplasms/*chemistry/pathology | 2 | 25.0 |
Logistic Models | 2 | 0.0 |
Nucleotides/metabolism | 2 | 5.0 |
Growth Substances/*pharmacology | 4 | 1.0 |
Autoantigens/*biosynthesis | 2 | 50.0 |
*Bone Marrow Cells | 2 | 0.0 |
Astrocytoma/*immunology/pathology | 2 | 100.0 |
*Tissue Fixation | 2 | 25.0 |
Epitopes | 3 | 0.0 |
Recombinant Proteins | 3 | 0.0 |
Actins/metabolism | 2 | 0.0 |
Genes, ras | 3 | 1.0 |
Lung Neoplasms/*chemistry | 2 | 11.0 |
Autoantibodies/analysis | 2 | 1.0 |
*Microwaves | 3 | 15.0 |
Nuclear Proteins/analysis/*biosynthesis | 3 | 33.0 |
Transforming Growth Factor alpha/pharmacology | 2 | 2.0 |
Skin Neoplasms/immunology/*pathology | 2 | 7.0 |
*Cyclin-Dependent Kinases | 2 | 1.0 |
*Protein Kinase Inhibitors | 2 | 3.0 |
Liver/*pathology | 4 | 7.0 |
Keratinocytes/*immunology/virology | 2 | 100.0 |
Mucous Membrane/pathology | 2 | 5.0 |
Neoplasms/*pathology | 2 | 3.0 |
*Protein Conformation | 2 | 0.0 |
Antigens, Neoplasm/analysis/*biosynthesis | 2 | 40.0 |
Nuclear Proteins/*biosynthesis | 5 | 11.0 |
Colon/chemistry/*pathology | 2 | 50.0 |
Antibodies, Antinuclear/*analysis | 2 | 7.0 |
Cell Transformation, Neoplastic/metabolism | 2 | 9.0 |
Nuclear Proteins/*immunology/metabolism | 2 | 100.0 |
Nuclear Proteins/analysis/*genetics | 2 | 14.0 |
Simian virus 40/*genetics | 3 | 5.0 |
Antigens, Neoplasm/*analysis/genetics | 2 | 12.0 |
Nuclear Proteins/*analysis/genetics | 3 | 23.0 |
DNA Repair/*drug effects | 3 | 9.0 |
Adenoma/chemistry/*pathology | 2 | 22.0 |
Receptor, erbB-2 | 4 | 2.0 |
*Papillomavirus, Human/isolation & purification | 2 | 100.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
Autoantigens/analysis | 5 | 17.0 |
Nuclear Proteins/*analysis/metabolism | 2 | 66.0 |
Bowen's Disease/*pathology | 2 | 100.0 |
Antigens, CD44/biosynthesis | 2 | 6.0 |
Receptors, Progesterone/biosynthesis | 2 | 6.0 |
Carcinoma, Intraductal, Noninfiltrating/chemistry/pathology | 2 | 100.0 |
Antigens, Neoplasm | 3 | 7.0 |
Prostate/cytology/*pathology | 2 | 66.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Prostatectomy | 2 | 2.0 |
Head and Neck Neoplasms/genetics/*pathology | 2 | 40.0 |
Drug Combinations | 3 | 0.0 |
Cell Cycle/*immunology | 2 | 50.0 |
Nuclear Proteins/immunology | 2 | 6.0 |
S Phase/immunology | 2 | 33.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Tumor Markers, Biological/*analysis/blood | 2 | 10.0 |
Liver Regeneration/*physiology | 2 | 8.0 |
Drug Administration Schedule | 2 | 0.0 |
Apoptosis/*drug effects/physiology | 2 | 1.0 |
Epidermal Growth Factor/*analysis | 2 | 1.0 |
Autoantibodies/*analysis | 2 | 0.0 |
Immunodiffusion | 2 | 0.0 |
Cell Nucleus/*immunology | 2 | 40.0 |
*Oncogenes | 2 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Bladder Neoplasms/*immunology/pathology | 2 | 28.0 |
Breast Neoplasms/pathology | 2 | 1.0 |
Megakaryocytes/*pathology | 2 | 6.0 |
Antigens, Neoplasm/*genetics | 2 | 3.0 |
*Hematopoiesis | 2 | 1.0 |
Autoantigens/metabolism | 2 | 4.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
*Ultrasonic Therapy | 2 | 50.0 |
Adenoma/*chemistry/pathology | 2 | 14.0 |
Cyclins | 2 | 20.0 |
Prostatic Hyperplasia/*metabolism | 2 | 4.0 |
Fibroblasts/immunology | 2 | 2.0 |
Nuclear Proteins/*biosynthesis/genetics | 3 | 12.0 |
Cell Survival/physiology | 2 | 1.0 |
Receptors, Estrogen/metabolism | 4 | 1.0 |
Receptors, Progesterone/metabolism | 3 | 1.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
Adenovirus Early Proteins | 2 | 2.0 |
Restriction Mapping | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Autoantigens/genetics | 2 | 5.0 |
Random Allocation | 2 | 0.0 |
Proteins/*metabolism | 2 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Antibodies, Antinuclear/analysis | 2 | 2.0 |
Nucleoproteins/*analysis | 2 | 100.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 2 | 1.0 |
Immunosorbent Techniques | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Proteins/genetics | 2 | 0.0 |
Monomeric GTP-Binding Proteins/*biosynthesis | 2 | 50.0 |
Transcription Factors/*biosynthesis | 2 | 1.0 |
Receptor, Epidermal Growth Factor/*biosynthesis | 2 | 1.0 |
